GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Notes Receivable

Satellos Bioscience (TSX:MSCL) Notes Receivable : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Notes Receivable?

Satellos Bioscience's Notes Receivable for the quarter that ended in Mar. 2024 was C$0.00 Mil.


Satellos Bioscience Notes Receivable Historical Data

The historical data trend for Satellos Bioscience's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Notes Receivable Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Satellos Bioscience Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Satellos Bioscience Notes Receivable Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines